Weight management
Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly on Thursday reported third-quarter revenue and adjusted earnings that topped estimates on strong demand for its diabetes drug Mounjaro, but slashed its full-year profit guidance due to charges primarily related to its recent acquisitions. Here’s […]
Read More
As Ozempic and Wegovy take off, this tech startup just lifted $20 million to deal with body weight loss with facts
Weight loss has usually been major organization, but it can be exploded of late thanks to surging demand for Ozempic, Wegovy and other new diabetes and being overweight prescription drugs. In the initially 50 percent of 2023, sales of Ozempic and Wegovy rose by 58% and 363%, respectively. Which is just after quarterly prescriptions for […]
Read More
‘Miracle drug’ euphoria: Specialists warn widespread use of fat decline medicine faces main hurdles
Two gurus see key difficulties facing the adoption of new being overweight medicine. Dr. Kavita Patel, a physician and NBC News health-related contributor, thinks new knowledge from Novo Nordisk on Ozempic’s means to hold off the development of long-term kidney disease is among the strongest supporting proof for secondary uses of the drug. On the […]
Read More
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
Danish drugmaker Novo Nordisk has entered a new chapter in its 100-year history — thanks to its newfound success with two products: Ozempic and Wegovy. The drugs are once-weekly injectables of a medication called semaglutide, prescribed for Type 2 diabetes and weight loss. Their skyrocketing popularity has boosted Novo Nordisk to new heights. Novo Nordisk’s […]
Read More
Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters U.S. health care providers wrote more than nine million prescriptions for Ozempic, Wegovy and similar diabetes and obesity drugs during […]
Read More
Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors – here’s what we know
An Ozempic (semaglutide) injection pen is seen on a kitchen table in Riga, Latvia on 06 August, 2023. Jaap Arriens | Nurphoto | Getty Images Heather Le Biller shed 9 pounds within the first week of taking Novo Nordisk‘s blockbuster diabetes drug Ozempic – and then even more as she continued treatment. Le Biller, a […]
Read More
Ozempic could be the next target of Medicare drug price negotiations – here’s why
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters Ozempic, the blockbuster diabetes treatment from Novo Nordisk, could be next in line for price negotiations between manufacturers and Medicare. […]
Read More
Weight loss drugs boost sales at retail pharmacies, but they may not help profits much
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters Drugmakers aren’t the only ones feeling the impact of the weight loss industry gold rush. Retailers with pharmacy businesses, such […]
Read More
Wegovy could prevent up to 1.5 million heart attacks, strokes over 10 years, study says
A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023. Jim Vondruska | Reuters Novo Nordisk’s blockbuster weight loss injection Wegovy could prevent up to 1.5 million heart attacks, strokes and other cardiovascular events in the U.S. over 10 years, according to […]
Read More
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion
Liselotte Sabroe | Afp | Getty Images Novo Nordisk on Thursday said it will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the Danish company’s blockbuster weight loss portfolio. The deal is Novo Nordisk’s latest attempt to capitalize on the weight loss industry gold rush, which began […]
Read More